Article (Scientific journals)
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Hanssens, Linda; van Winkel, Ruud; Wampers, Martien et al.
2008In Schizophrenia Research, 106 (2-3), p. 308-14
Peer Reviewed verified by ORBi
 

Files


Full Text
A cross-sectional evaluation of adiponectin_ocr.pdf
Author postprint (175.46 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Schizophrenia; Metabolic syndrome; Antipsychotic; Adiponectin; Diabetes
Abstract :
[en] BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The underlying mechanism, however, is poorly understood. Adiponectin is a recently identified adipocyte-derived protein, with low adiponectin levels being associated with metabolic abnormalities such as obesity, insulin resistance and type 2 diabetes. METHODS: Fasting adiponectin levels were assessed in a cross-sectional sample of 386 patients with schizophrenia or schizoaffective disorder. All patients were on monotherapy of second-generation antipsychotics (SGA) and underwent an extensive metabolic screening including an oral glucose tolerance test (OGTT). RESULTS: Adiponectin plasma levels were inversely correlated with BMI, and differed significantly between patients with normal weight, overweight or obesity (p<0.05). Patients who met criteria for the metabolic syndrome, according to adapted National Cholesterol Educational Program - Adult Treatment Panel criteria (NCEP-ATP III) (29.3%), had significantly lower adiponectin levels than patients not meeting metabolic syndrome criteria (p<0.0001). Patients without glucose abnormalities (78%) had significantly higher adiponectin levels than patients with diabetes (5.7%) (p<0.05). After controlling for components of metabolic syndrome and sex, antipsychotic medication independently influenced adiponectin levels (p<0.0001), with the lowest mean levels in patients on clozapine and olanzapine. CONCLUSIONS: Adiponectin levels in schizophrenic patients mirror what is observed in the general population, with the lowest levels in the most metabolically comprised subjects. However, antipsychotic medication may also influence adiponectin regulation independently, a finding that should be confirmed in longitudinal studies.
Disciplines :
Psychiatry
Public health, health care sciences & services
Endocrinology, metabolism & nutrition
Author, co-author :
Hanssens, Linda
van Winkel, Ruud
Wampers, Martien
Van Eyck, Dominique
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Reginster, Jean-Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Collette, Julien ;  Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Peuskens, Joseph
De Hert, Marc
Language :
English
Title :
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Publication date :
2008
Journal title :
Schizophrenia Research
ISSN :
0920-9964
Publisher :
Elsevier, Amsterdam, Netherlands
Volume :
106
Issue :
2-3
Pages :
308-14
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
All our thanks to elsevier
Available on ORBi :
since 28 March 2011

Statistics


Number of views
198 (8 by ULiège)
Number of downloads
331 (0 by ULiège)

Scopus citations®
 
45
Scopus citations®
without self-citations
41
OpenCitations
 
36

Bibliography


Similar publications



Contact ORBi